Hospital
Memorial Hospital
Memorial Hospital was paid $38.95M by Medicaid between Jan 2018 and Dec 2024, across 450 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 30% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL
OWOSSO, MI 48867
OWOSSO, MI 48867
33aNPI1063414233assigned 06/01/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$38.95M
24GClaims1,394,807
24DCodes billed450
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#32 of 86
Median peer was paid$21.55M
This provider vs. median1.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 156,294 | $4.89M | |
| 2019 | 188,900 | $4.43M | |
| 2020 | 176,693 | $4.14M | |
| 2021 | 230,953 | $5.95M | |
| 2022 | 226,999 | $6.50M | |
| 2023 | 229,332 | $6.88M | |
| 2024incomplete | 185,636 | $6.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 30% | 244,981 | 207,115 | $11.51M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 20,859 | 19,511 | $3.85M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 28,569 | 26,628 | $3.43M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.2% | 8,301 | 7,871 | $3.19M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 12,232 | 11,196 | $1.18M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 2.2% | 3,781 | 1,563 | $872K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 5,561 | 5,375 | $818K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 30,319 | 8,183 | $799K |
| J2350 | Injection, ocrelizumab, 1 mg | 1.6% | 48 | 48 | $610K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 6,547 | 5,164 | $591K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 15,743 | 14,739 | $539K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.3% | 2,133 | 2,081 | $513K |
438 more codes
| 20610 | 1.2% | 3,556 | $471K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 1,355 | $451K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 6,328 | $422K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,563 | $353K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 11,294 | $346K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,771 | $315K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,615 | $312K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 609 | $294K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24,188 | $245K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,157 | $234K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,050 | $213K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,754 | $212K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,016 | $190K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 339 | $186K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,123 | $182K |
| 76830 | Ultrasound, transvaginal | <1% | 3,404 | $182K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,725 | $178K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 12,366 | $177K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 11,842 | $174K |
| 64615 | <1% | 1,416 | $172K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,639 | $168K |
| 80061 | Lipid panel | <1% | 18,491 | $160K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,055 | $149K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18,053 | $144K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,280 | $138K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,045 | $135K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 11,653 | $126K |
| 76801 | <1% | 2,451 | $125K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,761 | $122K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,362 | $119K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,996 | $103K |
| 97162 | <1% | 2,072 | $102K | |
| 86008 | <1% | 931 | $102K | |
| G0378 | Hospital observation service, per hour | <1% | 1,468 | $96K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 186 | $94K |
| 80053 | Comprehensive metabolic panel | <1% | 52,218 | $88K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,576 | $84K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,831 | $79K |
| 47562 | <1% | 24 | $78K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,461 | $77K |
| 96367 | <1% | 2,413 | $74K | |
| 96415 | <1% | 1,339 | $73K | |
| 97161 | <1% | 1,505 | $72K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,772 | $71K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,044 | $69K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,292 | $67K |
| 93975 | <1% | 552 | $66K | |
| 90677 | <1% | 998 | $65K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,216 | $65K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,478 | $65K |
| 64493 | <1% | 123 | $64K | |
| 90651 | <1% | 2,119 | $63K | |
| 94060 | <1% | 438 | $62K | |
| 59025 | Fetal non-stress test | <1% | 622 | $60K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 523 | $57K |
| 90686 | <1% | 8,189 | $57K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 439 | $55K |
| 76770 | <1% | 961 | $55K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 61,786 | $54K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,248 | $53K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,858 | $53K |
| 17110 | <1% | 1,180 | $53K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 754 | $50K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 4,219 | $49K |
| 76536 | <1% | 920 | $45K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,625 | $44K |
| 93971 | <1% | 836 | $43K | |
| 71250 | <1% | 881 | $42K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,273 | $41K |
| 73630 | <1% | 3,401 | $39K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,190 | $39K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,375 | $38K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 412 | $38K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,267 | $35K |
| 76642 | <1% | 916 | $33K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,783 | $33K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,874 | $32K |
| 97035 | <1% | 5,796 | $30K | |
| 72141 | <1% | 284 | $30K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 708 | $29K |
| 93017 | <1% | 555 | $28K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,443 | $28K |
| 71271 | <1% | 462 | $26K | |
| 73610 | <1% | 2,669 | $25K | |
| 73564 | <1% | 2,048 | $25K | |
| 73130 | <1% | 2,876 | $24K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 922 | $24K |
| 82607 | <1% | 5,372 | $22K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 70 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,565 | $22K |
| 80055 | <1% | 1,165 | $22K | |
| 95806 | <1% | 266 | $22K | |
| 95117 | <1% | 1,975 | $21K | |
| 90474 | <1% | 3,487 | $21K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,534 | $21K |
| 72156 | <1% | 191 | $20K | |
| 73110 | <1% | 2,043 | $20K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,506 | $20K |
| 72110 | <1% | 1,117 | $20K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,753 | $19K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 955 | $19K |
| 72100 | <1% | 957 | $19K | |
| 90670 | <1% | 5,238 | $18K | |
| 73030 | <1% | 2,813 | $18K | |
| 82728 | <1% | 4,351 | $18K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,862 | $18K |
| 84439 | <1% | 6,455 | $17K | |
| 87088 | <1% | 11,453 | $17K | |
| 87581 | <1% | 1,573 | $17K | |
| 87486 | <1% | 1,573 | $17K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 95 | $16K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 24 | $15K |
| 84702 | <1% | 4,729 | $15K | |
| 92557 | <1% | 1,245 | $15K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 37 | $14K |
| 87653 | <1% | 1,085 | $14K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,930 | $14K |
| 87070 | <1% | 5,754 | $13K | |
| 81025 | <1% | 14,058 | $12K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,835 | $12K |
| 90682 | <1% | 222 | $12K | |
| 83516 | <1% | 1,049 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 293 | $11K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 47 | $11K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 13 | $11K |
| 73501 | <1% | 534 | $11K | |
| 83655 | <1% | 2,790 | $11K | |
| 86803 | <1% | 2,149 | $11K | |
| 84403 | <1% | 1,341 | $10K | |
| 80074 | <1% | 780 | $10K | |
| 77080 | <1% | 175 | $10K | |
| 77066 | Tomosynthesis, mammo | <1% | 174 | $10K |
| 83550 | <1% | 3,812 | $10K | |
| 73560 | <1% | 1,174 | $9K | |
| S4005 | Interim labor facility global (labor occurring but not resulting in delivery) | <1% | 78 | $9K |
| 90621 | <1% | 356 | $9K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 738 | $9K |
| 87505 | <1% | 209 | $9K | |
| 64405 | <1% | 55 | $8K | |
| 36591 | <1% | 362 | $8K | |
| 83880 | <1% | 2,775 | $8K | |
| 86787 | <1% | 1,372 | $8K | |
| 83540 | <1% | 4,203 | $8K | |
| 82746 | <1% | 1,790 | $8K | |
| 86038 | <1% | 2,233 | $8K | |
| 87186 | <1% | 4,116 | $7K | |
| 86900 | <1% | 2,516 | $7K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,124 | $7K |
| 87077 | <1% | 4,384 | $7K | |
| 84402 | <1% | 913 | $7K | |
| 90734 | <1% | 1,132 | $7K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 257 | $7K |
| 82652 | <1% | 614 | $7K | |
| 81002 | <1% | 8,053 | $6K | |
| 86140 | <1% | 5,948 | $6K | |
| 74018 | <1% | 471 | $6K | |
| 64483 | <1% | 12 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,288 | $5K |
| 82784 | <1% | 1,174 | $5K | |
| 70486 | <1% | 138 | $5K | |
| 94799 | <1% | 2,937 | $5K | |
| 81003 | <1% | 21,060 | $5K | |
| 92567 | <1% | 2,343 | $5K | |
| 87634 | <1% | 285 | $5K | |
| 84146 | <1% | 808 | $5K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 701 | $5K |
| 85651 | <1% | 4,546 | $5K | |
| 82043 | <1% | 2,911 | $5K | |
| 97163 | <1% | 89 | $4K | |
| 90480 | <1% | 108 | $4K | |
| 73080 | <1% | 484 | $4K | |
| 83735 | <1% | 6,360 | $4K | |
| 82785 | <1% | 740 | $4K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 77 | $4K |
| 69210 | <1% | 350 | $4K | |
| 85610 | <1% | 6,620 | $4K | |
| 93970 | <1% | 39 | $4K | |
| 86480 | <1% | 206 | $4K | |
| 87480 | <1% | 997 | $4K | |
| 0012A | <1% | 122 | $4K | |
| 84550 | <1% | 2,628 | $4K | |
| 82670 | <1% | 398 | $4K | |
| 85027 | <1% | 3,758 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 14 | $4K |
| 10060 | <1% | 41 | $4K | |
| 87660 | <1% | 944 | $4K | |
| 83001 | <1% | 644 | $4K | |
| 73221 | <1% | 25 | $4K | |
| 97165 | <1% | 79 | $4K | |
| 87510 | <1% | 956 | $3K | |
| 80076 | <1% | 2,063 | $3K | |
| 84166 | <1% | 669 | $3K | |
| 87081 | <1% | 1,566 | $3K | |
| 90716 | <1% | 1,368 | $3K | |
| 86481 | <1% | 97 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 43 | $3K |
| 73562 | <1% | 1,116 | $3K | |
| 72050 | <1% | 132 | $3K | |
| 86255 | <1% | 700 | $3K | |
| 86780 | <1% | 582 | $3K | |
| 88304 | <1% | 959 | $3K | |
| 76882 | <1% | 64 | $3K | |
| 97014 | <1% | 307 | $3K | |
| 90732 | <1% | 45 | $3K | |
| 81001 | <1% | 10,479 | $3K | |
| 84112 | <1% | 80 | $3K | |
| 93226 | <1% | 91 | $3K | |
| 90688 | <1% | 299 | $3K | |
| 83690 | <1% | 9,259 | $3K | |
| 82570 | <1% | 1,509 | $3K | |
| G0010 | Administration of hepatitis b vaccine | <1% | 362 | $2K |
| 73100 | <1% | 114 | $2K | |
| 73590 | <1% | 281 | $2K | |
| 70491 | <1% | 27 | $2K | |
| 0011A | <1% | 99 | $2K | |
| 82950 | <1% | 1,166 | $2K | |
| 86850 | <1% | 2,014 | $2K | |
| 95911 | <1% | 12 | $2K | |
| 29075 | <1% | 14 | $2K | |
| 83002 | <1% | 354 | $2K | |
| 95909 | <1% | 13 | $2K | |
| 85730 | <1% | 3,359 | $2K | |
| 82105 | <1% | 384 | $2K | |
| 86431 | <1% | 1,086 | $2K | |
| 97166 | <1% | 38 | $2K | |
| 82947 | <1% | 1,161 | $2K | |
| 85378 | <1% | 2,445 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 43 | $2K |
| 87147 | <1% | 1,238 | $2K | |
| 82805 | <1% | 516 | $2K | |
| 73090 | <1% | 217 | $2K | |
| 85018 | <1% | 2,257 | $2K | |
| 25600 | <1% | 13 | $2K | |
| 36600 | <1% | 97 | $2K | |
| 85007 | <1% | 2,812 | $2K | |
| 82550 | <1% | 1,612 | $1K | |
| 93225 | <1% | 42 | $1K | |
| 90619 | <1% | 771 | $1K | |
| 0002A | <1% | 39 | $1K | |
| 82962 | <1% | 7,289 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 112 | $1K |
| 83721 | <1% | 405 | $1K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 13 | $1K |
| 80069 | <1% | 665 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 85 | $1K |
| 83970 | <1% | 100 | $1K | |
| 83993 | <1% | 214 | $1K | |
| 82565 | <1% | 977 | $1K | |
| 84100 | <1% | 1,892 | $1K | |
| 82150 | <1% | 1,594 | $1K | |
| 87899 | <1% | 202 | $1K | |
| 90744 | <1% | 2,195 | $1K | |
| 20550 | <1% | 13 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 80 | $1K |
| 94760 | <1% | 1,916 | $1K | |
| 70496 | <1% | 40 | $1K | |
| 74019 | <1% | 42 | $971.98 | |
| 90473 | <1% | 79 | $968.36 | |
| 73502 | <1% | 103 | $952.89 | |
| 84481 | <1% | 215 | $921.05 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 25 | $917.77 |
| 86376 | <1% | 194 | $911.13 | |
| 99495 | <1% | 15 | $896.47 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 40 | $884.63 |
| 0001A | <1% | 42 | $880.90 | |
| 99406 | <1% | 87 | $874.12 | |
| 58300 | <1% | 51 | $873.15 | |
| 91320 | <1% | 13 | $849.85 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 764 | $839.57 |
| 87340 | <1% | 222 | $746.39 | |
| 94010 | <1% | 209 | $697.97 | |
| 86901 | <1% | 2,502 | $670.17 | |
| 87205 | <1% | 954 | $633.47 | |
| 72114 | <1% | 29 | $584.61 | |
| 82248 | <1% | 381 | $546.00 | |
| 89220 | <1% | 85 | $532.77 | |
| 82533 | <1% | 68 | $516.54 | |
| 84450 | <1% | 295 | $473.34 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 358 | $468.46 |
| 0071A | <1% | 12 | $450.36 | |
| 86671 | <1% | 112 | $443.76 | |
| 73140 | <1% | 56 | $441.89 | |
| 90656 | <1% | 192 | $431.52 | |
| 71101 | <1% | 25 | $430.30 | |
| 82247 | <1% | 216 | $428.18 | |
| 84484 | <1% | 7,000 | $416.25 | |
| 83605 | <1% | 4,996 | $403.28 | |
| 92083 | <1% | 269 | $397.48 | |
| 76870 | <1% | 26 | $361.80 | |
| 87641 | <1% | 51 | $348.90 | |
| 87040 | <1% | 3,235 | $346.01 | |
| 72072 | <1% | 12 | $324.20 | |
| 94726 | <1% | 157 | $312.54 | |
| 96381 | <1% | 18 | $295.02 | |
| 86778 | <1% | 44 | $276.99 | |
| 11721 | <1% | 24 | $254.61 | |
| 82977 | <1% | 88 | $231.77 | |
| 87045 | <1% | 99 | $230.87 | |
| 29125 | <1% | 54 | $228.30 | |
| 84460 | <1% | 163 | $226.50 | |
| 83520 | <1% | 38 | $224.80 | |
| 84478 | <1% | 122 | $213.12 | |
| 87430 | <1% | 130 | $210.33 | |
| 83615 | <1% | 166 | $207.76 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 13 | $199.80 |
| 93270 | <1% | 12 | $197.48 | |
| 86141 | <1% | 81 | $181.19 | |
| 84703 | <1% | 394 | $173.76 | |
| 72070 | <1% | 12 | $167.13 | |
| 80164 | <1% | 28 | $154.54 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 13 | $150.36 |
| 72040 | <1% | 12 | $144.99 | |
| 88174 | <1% | 20 | $144.85 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 339 | $130.68 |
| 86777 | <1% | 25 | $121.93 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,089 | $117.88 |
| 86580 | <1% | 44 | $117.84 | |
| 90633 | <1% | 3,480 | $113.00 | |
| 12001 | <1% | 267 | $107.29 | |
| 86039 | <1% | 41 | $101.71 | |
| 90648 | <1% | 498 | $97.00 | |
| 86706 | <1% | 26 | $94.11 | |
| 84153 | <1% | 15 | $90.89 | |
| 73120 | <1% | 15 | $84.29 | |
| 82103 | <1% | 12 | $84.03 | |
| 84165 | <1% | 26 | $82.00 | |
| 85044 | <1% | 71 | $80.66 | |
| 70498 | <1% | 39 | $79.37 | |
| 82172 | <1% | 12 | $75.07 | |
| 86665 | <1% | 12 | $71.82 | |
| 82465 | <1% | 39 | $71.51 | |
| 95886 | <1% | 1,583 | $65.60 | |
| 86225 | <1% | 12 | $63.47 | |
| 90660 | <1% | 18 | $57.74 | |
| 90672 | <1% | 79 | $53.80 | |
| 87076 | <1% | 68 | $50.34 | |
| 87807 | <1% | 187 | $43.85 | |
| 90715 | <1% | 3,985 | $40.62 | |
| 83010 | <1% | 13 | $37.87 | |
| 87106 | <1% | 25 | $37.75 | |
| 84145 | <1% | 13 | $35.96 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 2,531 | $34.71 |
| 87109 | <1% | 17 | $33.78 | |
| 87184 | <1% | 14 | $33.36 | |
| 86308 | <1% | 96 | $33.11 | |
| 86664 | <1% | 12 | $30.27 | |
| 86200 | <1% | 12 | $28.31 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,931 | $26.86 |
| 90658 | <1% | 14 | $22.85 | |
| 82044 | <1% | 29 | $22.45 | |
| 86592 | <1% | 14 | $22.20 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 12 | $13.68 |
| 82140 | <1% | 12 | $9.59 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,939 | $7.20 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 336 | $6.34 |
| 82010 | <1% | 26 | $5.38 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 2,189 | $5.11 |
| 84436 | <1% | 125 | $5.03 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,142 | $5.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 348 | $4.50 |
| 36416 | <1% | 1,118 | $4.32 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,932 | $2.11 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,927 | $1.76 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,889 | $0.31 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,346 | $0.08 |
| 90698 | <1% | 4,138 | $0.01 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 618 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 8,342 | $0.00 |
| 90697 | 0% | 1,013 | $0.00 | |
| 90696 | 0% | 1,472 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 176 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 333 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,378 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 931 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 832 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,152 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 5,875 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 223 | $0.00 |
| J3490 | Unclassified drugs | 0% | 3,345 | $0.00 |
| 96376 | 0% | 2,516 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 143 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 7,040 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,032 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 2,565 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 218 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,212 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 966 | $0.00 |
| 90680 | 0% | 4,023 | $0.00 | |
| 64494 | 0% | 70 | $0.00 | |
| 95012 | 0% | 63 | $0.00 | |
| 84479 | 0% | 105 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 741 | $0.00 |
| 91307 | 0% | 57 | $0.00 | |
| 90632 | 0% | 120 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 35 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 42 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 14 | $0.00 |
| 99058 | 0% | 32 | $0.00 | |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 61 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 24 | $0.00 |
| 91318 | 0% | 15 | $0.00 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 0% | 19 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 16 | $0.00 |
| 12002 | 0% | 14 | $0.00 | |
| C1769 | Guide wire | 0% | 14 | $0.00 |
| 94150 | 0% | 658 | $0.00 | |
| 90707 | 0% | 1,472 | $0.00 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 2,355 | $0.00 |
| 90710 | 0% | 1,556 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 2,304 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 31 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 912 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 3,430 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 3,574 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 3,664 | $0.00 |
| 90700 | 0% | 844 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 3,407 | $0.00 |
| 90685 | 0% | 483 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 55 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 136 | $0.00 |
| 94729 | 0% | 247 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 67 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 167 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 289 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 38 | $0.00 |
| 90687 | 0% | 16 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 278 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 19 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 188 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 42 | $0.00 |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 23 | $0.00 |
| 69209 | 0% | 13 | $0.00 | |
| 87210 | 0% | 26 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 12 | $0.00 |
| 82731 | 0% | 15 | $0.00 | |
| 92133 | 0% | 72 | $0.00 | |
| 88302 | 0% | 14 | $0.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 20 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTREMAIN, JORRI (CFO)
| Provider | Location | Paid |
|---|---|---|
| Memorial Hospital | Owosso, MI | $17.34M |
| Memorial Hospital | Durand, MI | $1.16M |
| Memorial Hospital | Owosso, MI | $1.00M |
| Memorial Hospital | Owosso, MI | $627K |
| Memorial Hospital | Owosso, MI | $304K |
| Memorial Hospital | Flushing, MI | $112K |
| Memorial Hospital | Owosso, MI | $88K |
| Memorial Hospital | Owosso, MI | $261.34 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.